<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571337</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2005-1</org_study_id>
    <nct_id>NCT00571337</nct_id>
  </id_info>
  <brief_title>Stop Infliximab in Patients With Crohn's Disease</brief_title>
  <acronym>STORI</acronym>
  <official_title>Prospective Study of Predictive Factors of Sustained Remission of Crohn's Disease After Stopping Infliximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1 Project summary 1.1 Rational. Accent 1 study has demonstrated the superiority of Infliximab
      over placebo in a systematic treatment strategy of Crohn 's disease every 8 weeks during one
      year. However the optimal strategy beyond one year of treatment is not established.
      Particularly, the need for carrying on systematic treatment with infliximab in all the
      patients has not been demonstrated.

      1.2 Primary objective. Determine factors associated with a low risk of clinical relapse after
      stopping infliximab in CD patients in remission (CDAI&lt;150) and regularly treated with
      infliximab for at least one year.

      1.3 Main objective and main judgement criteria. Determine predictive factors for relapse
      within one year after stopping infliximab. Main judgement criteria is the clinical relapse
      after stopping infliximab. Clinical relapse is defined either by a CDAI&gt;250 or by a CDAI
      between 150 and 250 if this CDAI is confirmed over two consecutive weeks with an increase of
      at least 70 points over baseline for the two consecutive measures.

      1.4 Secondary objectives and judgement criteria. Determine the time to-relapse Determine
      predictive factors for short-term relapse (&lt;2 months)after stopping infliximab.

      Determine response to infliximab retreatment in these patients. Determine tolerance to
      infliximab retreatment in these patients. Determine predictive factors for an absence of
      response to retreatment. Determine predictive factors for infliximab retreatment intolerance.
      Determine sustained response in the retreated patients.

      1.5 Type of study Open-label prospective study of stopping regular treatment. Inclusion
      period: minimum one year, possibly prolonged to reach 100 patients. Patients will be followed
      up every two months for at least 18 months after stopping infliximab.

      1.6 Justification of the number of patients Number of patients to include is at least 100.
      This recruitment should be reached within one year. This number should allow to disclose
      predictive factors associated with a relative risk of at least 2 if this factor is
      equilibrated (50% at risk patients) or 3 is this factor is disequilibrated (90% at risk
      patients).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse of Crohn's disease assessed by a CDAI &gt; 250 or a CDAI between 150 and 250 at two consecutive weeks, with an increase of at least 70 points over baseline.</measure>
    <time_frame>Time to relapse over one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of demographic, clinical and endoscopic factors predictive of relapse of Crohn's disease after stopping infliximab, with univariate and multivariate analysis.</measure>
    <time_frame>Factors influencing time to relapse over one year.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance and safety of infliximab retreatment in patients experiencing a relapse.</measure>
    <time_frame>Follow up over 4 months including 3 infliximab retreatment s.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive factors of short term-relapse (&lt;2 months) after stopping infliximab, in the follow up of the patients.</measure>
    <time_frame>at least 12 month and a maximum of 18 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response to infliximab retreatment, assessed 4 weeks after retreatment using CDAI. A clinical response is defined by a 70 points drop (and at least 25%) as compared to relapse CDAI.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">126</enrollment>
  <condition>Crohn Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Crohn's disease.

          -  Age &gt; 18 years.

          -  Patient written informed consent.

          -  Patient having been treated with infliximab for confirmed Crohn's disease with active
             intestinal lesions.

          -  Patient treated with infliximab for at least 1 year, associated with an
             immunosuppressor for at least one year, with a maximum interval between 2 infliximab
             infusions of 3 months.

          -  Patient with continuous remission without steroids for at least 6 months, except IV
             steroids for infusion reaction prophylaxis.

          -  CDAI&lt;150.

          -  Contraception all over the study.

        Exclusion criteria:

          -  Patient having experienced an severe acute infusion reaction to infliximab, defined by
             an anaphylacto√Ød reaction (drop in blood pressure, bronchospasm, dyspnea) requiring
             the arrest of the infliximab infusion.

          -  Patient having experienced a severe delayed infusion reaction to infliximab, defined
             by fever, arthralgia, myalgia, requiring a steroid treatment.

          -  Patient with dominant perianal disease and absence of active intestinal disease at the
             time of infliximab induction.

          -  Patient with active perianal disease at the time of inclusion.

          -  Patient with stoma.

          -  Patient with debilitating extra-intestinal manifestation at the time of inclusion.

          -  Non cooperating subjects.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis Edouard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU LIEGE - Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Marseille - Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Le Raincy Montfermeil</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU LYON</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002 Sep;97(9):2357-63.</citation>
    <PMID>12358256</PMID>
  </reference>
  <reference>
    <citation>Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002 Sep;123(3):707-13.</citation>
    <PMID>12198696</PMID>
  </reference>
  <reference>
    <citation>Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003 Apr;124(4):917-24.</citation>
    <PMID>12671888</PMID>
  </reference>
  <reference>
    <citation>Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 Feb 13;348(7):601-8.</citation>
    <PMID>12584368</PMID>
  </reference>
  <reference>
    <citation>Tampo Y, Yonaha M. Antioxidant mechanism of Mn(II) in phospholipid peroxidation. Free Radic Biol Med. 1992;13(2):115-20.</citation>
    <PMID>1516837</PMID>
  </reference>
  <reference>
    <citation>Parsi MA, Lashner BA. Safety of infliximab: primum non nocere. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Inflamm Bowel Dis. 2004 Jul;10(4):486-7.</citation>
    <PMID>15475765</PMID>
  </reference>
  <reference>
    <citation>Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098-104.</citation>
    <PMID>11596589</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>July 22, 2010</last_update_submitted>
  <last_update_submitted_qc>July 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>LEMANN MARC</name_title>
    <organization>getaid</organization>
  </responsible_party>
  <keyword>Stop infliximab.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

